84

i) Pattern of relapse was following:

OIsease No. No. I n i t i a l relapse s i t e extent CRs relapsed Chest CNS Others

CT alone ED 16 13 8 3 4 CT alone CO 12 9 7 2 0 CT plus RT LD 22 ]4 8 S 5

2) Patient survival Median survival time (MST) was 15.0 mos for both CRs given CT alone and those given CT plus RT. However, among 22 LD who achieved CR with CT plus RT, those who responded completely to CT and con- solidated by RT lived longer than those who responded partially to CT and achieved CR by RT. (MST, 22.0 mos vs 13.0 mos; 2 year-survivor, 5/14 vs 0/8).

In our conclusion: i) there were no dif- ferences in relapse pattern and patient survival between CRs treated with CT alo- ne and CT plus RT. 2) •ocoregional RT im- proved duration of CR and patient survival, when given to CRs to CT. 3) PCI showed a trend to reduce CNS metastases and to improve patient survival.

Long-Term Survivors in Small Cell Lung Can-

"~ " [~CLC). 1 1 c e r Crino,~ L., Darwish , ~., Tonato , M., Latini , P., Maranzano , E. i. Servizio di Oncologia Medica. 2. Servizio di Radio- terapia, Policlinico, 06100 Perugia, Italy.

Fifty two previously untreated patients with limited disease SCLC were treated between Oct., 1979 and March, 1983 with CAV combination chemotherapy (CT~: cytox- an 750 mg/m-, adriamycin 40 mg/m- every 3 wks and vincristine 1 mg wkly for 12 wks, for 2 cycles, followed by chest and brain radiotherapy (RT) and then by the same CT without vincristine for a maximum of 2 yrs. Twenty (38.5%) complete remissions (CR) and 20 partial remissions were documented. Eight patients in CR were defined as long- term survivors with a duration of CR ran- ging between 30 and 77 months. All were males and at presentation 7 of the 8 had a performance status of 0. Three stage I patients (TI-^N^M^) had previously under- z u u gone lung surgery and received at least 4 cycles of CT plus brain prophylactic RT. One patient relapsed in the chest (documented only by bronchoscopy during follow up) at 26 months, and experienced a new CR with salvage CT (Vp-16, CCNU, CTX) still in effect at 62 months. Two patients died of heart disease at 30 and 42 months while in clinical CR. One patient had se- vere neurological symptoms (ataxia) with brain atrophy and ventricular dilatation documented by CAT. Six patients remain alive and symptom free despite some pul- monary fibrosis in all the 4 irradiated cases.

Our experience confirms that good qua- lity long-term survival is possible in

limited disease SCLC and that close fol-

low up is mandatory to detect late relapses

(after 2 yrs) because of the potential efficacy of a salvage therapy.

Clinical Effects of the Therapy Based on The Improvement of I,~ntmo-Survei]lance System Against Lung Cancer. sato, I., Kaneko, Y., Okada, N. Institute of Biodefence Mechanism, Kawasaki, Japan.

The process of our treatment consists of the following two steps. The first step is libera- tion of the antigenic components from cancer cells by regional irradiation or systemic anti- cancer drug administration with a relatively small dose. The second step is recognition of the antigen liberated with 50 millions of allogeneic lymphocytes infused intravenesously. These two steps are to be repeated at adequate intervals in each case.

As the results, 83 lung cancer patients in- cluding metastatic tumor in terminal stage of cancer with poor prognosis were received the therapy. About 55% of the patients with prima- ry lung cancer were rated effective and 62% of the patients with metastatic lung cancer were rated effective. In 25% of the patients received this therapy, the size of tumors were

reduced by half or the tumors disappeared.

Evaluation of Computed Radiography in the Ima- g ing of Lung Cancer. Takizawa, H., Tabeta, H., Anzaki, Y., Kikuchi, N. Department of Chest Mad., Shioya Hospital, Yaita City, 239-21: Mizutani, F., Saitoh, M., Nagao, K., Shimura, A., Watanabe, S. Institute of Pulmonary Cancer Research, School of Medi- cine, Chiba University, Ogata, T. Department of Pathology, Tsukuba University School of Medi- cine, Japan.

Computed radiography utilizing scanning laser stimulated luminescence (FCR) ; a recent- ly developed diagnostic modality realizing, by contrast and spatial frequency enhancements, much wider and more flexible image reproduction range compared with conventional screen-film system; was applied to lung cancer to inve- stigate the efficacy in the imaging of prima- ry and metastatic lesions.

Fifteen primary lung cancers aged 61.2+ 10.3 (SD) years, consisting of 8 Ad, 5Ep and 2 Sm cases with 5 in stage I, 1 in II, 4 in III and 5 in IV and four metastatic cancers from other organs underwent FCR following con- ventional radiography. Tomography was routine- ly accompanied and 3-time magnification was partially added using 0.1 man tube. The results were carefully examined by 6 doctors, including comparison with x ray CT.

Remarkable image improvement was observed in FCR tomography recorded under spatial frequen- cy enhancement peaking 0.31-0.50 cycles/mm, providing far clearer findings of the periphe- ral nodules and their surrounding tissues. Vi- sualization of hilum and mediastinum was also

better resembling xerotomography. Significant